Related Experiment Video
Updated: Sep 30, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus
Shoji Natsugoe1, Che Xiangming, Masataka Matsumoto
1First Department of Surgery, School of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. natsugoe@m2.kufm.kagoshima-u.ac.jp
Purpose:
The members of the Smad family play key rolesin regulating gene expression in the transforming growth factor (TGF)-beta1 signaling pathways. Activation of Smads causes their translocation from the cytoplasm to the nucleus, where they function as transcription factors. The present study analyzed the expression and clinicopathological significance of Smad4 and TGF-beta1 in squamous cell carcinoma of the esophagus.
Experimental Design:
Immunohistochemistry was used to investigate the expression of Smad4 and TGF-beta1 proteins in 258 patients with squamous cell carcinoma of the esophagus. The relationship between expression of these proteins and clinicopathological factors was analyzed, and the usefulness of Smad4 in disease prognosis was evaluated in relation to TGF-beta1 expression.
Results:
Smad4 expression was preserved in 32.2% of tumors, and TGF-beta1 expression was identified in 42.6% of tumors. Patients with preserved expression of Smad4 had a higher rate of early-stage carcinoma (P < 0.01) and fewer lymph node metastases (P < 0.01) than those with reduced Smad4 expression. The expression of TGF-beta1 was not associated with any of the clinicopathological factors. Postoperative survival analysis indicated that patients with a tumor in which Smad4 expression was reduced had worse clinical outcomes than those with preserved expression (P = 0.01). In patients with TGF-beta1-negative tumors, the survival rate was significantly higher in patients with a preserved level of Smad4 expression than in those with reduced Smad4 expression (P = 0.02). However, according to multivariate analysis, Smad4 expression could not be used as an independent prognostic factor.
Conclusions:
Although Smad4 expression could not be used as a prognostic factor, its expression reflected tumor progression such as tumor depth and lymph node metastasis.
Insights
Smad4 expression in esophageal squamous cell carcinoma correlates with tumor stage and lymph node metastasis. Reduced Smad4 levels indicate poorer prognosis, though it
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Smad proteins are key regulators in transforming growth factor (TGF)-beta1 signaling pathways.
- Smad activation leads to nuclear translocation, where they function as transcription factors.
Purpose of the Study:
- To analyze the expression of Smad4 and TGF-beta1 in esophageal squamous cell carcinoma.
- To determine the clinicopathological significance of Smad4 and TGF-beta1 expression.
Main Methods:
- Immunohistochemistry was employed to assess Smad4 and TGF-beta1 protein expression in 258 esophageal squamous cell carcinoma patients.
- Statistical analyses were performed to correlate protein expression with clinicopathological factors and patient survival.
Main Results:
- Smad4 expression was preserved in 32.2% of tumors, and TGF-beta1 in 42.6%.
- Preserved Smad4 expression was associated with early-stage disease and fewer lymph node metastases (P < 0.01).
- Reduced Smad4 expression correlated with worse patient outcomes (P = 0.01), particularly in TGF-beta1-negative tumors (P = 0.02).
Conclusions:
- Smad4 expression reflects tumor progression, including depth and lymph node metastasis, in esophageal squamous cell carcinoma.
- While not an independent prognostic factor, Smad4 expression provides valuable insights into disease characteristics.
